FDA approves Novoste's 60mm radiation source:
This article was originally published in Clinica
Executive Summary
The US FDA has given Novoste the green light to market its Beta-Cath system with a longer 60mm radiation source, which is suitable for the treatment of long, diffuse in-stent restenosis. Patients with diffuse, in-stent restenosis typically have the worst clinical outcomes due to the complexity of their disease, says the Atlanta, Georgia firm. The Beta-Cath product line already includes 30-mm and 40mm radiation source lengths.